Resources for Researchers

NIAID offers many resources to support your research, including reagents, model organisms, and tissue samples, to name just a few. Use the filters under Filter Search Results to narrow your search, or simply enter specific search terms in the search field.

This contract provides gap-filling support services for HIV prevention drug developers including academic (investigators), for-profit and not-for-profit small and large companies, and other product innovators (henceforth identified as Sponsors) for the development of HIV non-vaccine biomedical pr

The RSC Public Website, run by the DAIDS Regulatory Support Center (RSC) contractor, has been used in the DAIDS community for over 10 years and is a primary platform to communicate updates to templates, process changes, and other information needed by the RSC research community.

This service provides follow-up studies of products which already have been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development of the product as an HIV therapeutic.

This service provides evaluation of products in animal efficacy models. A product must demonstrate a potent and selective activity profile in vitro against the HIV strain used in the model prior to its acceptance as a candidate for this service.

This service program supports the development and manufacture, of a wide variety of pharmaceutical dosage formulations, including tablets, capsules, semi-solid preparations, injectibles, and sustained-release products. If requested, manufacturing can be done under GMP.

This service provides chemical synthesis of lead compounds for use in additional drug development studies. Compounds must previously have been successfully synthesized to be candidates for this service. Synthesis of new analogs is not supported.

The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical speci

This service provides evaluation of products that have already been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development as a microbicide.

The Multicenter AIDS Cohort Study (MACS) is an ongoing prospective study of the natural and treated histories of HIV-1 infection in homosexual and bisexual men conducted by sites located in Baltimore, Chicago, Pittsburgh and Los Angeles.

Researchers involved with the NIAID Clinical Genomics Program study many diseases of the immune system that are rare and not well understood but often shed light on basic immune function and more common immune disorders.

The National Institutes of Health (NIH) AIDS Reagent Program provides critical research reagents and resources to the scientific community. The ARP acquires, develops, and produces state-of-the-art reagents and provides these reagents at no cost to qualified investigators throughout the world.

The Preclinical Development Support Master Contract (PDSMC) supports all phases of preclinical development, including process and product development, GMP manufacturing and clinical lot production, analytical and formulation, preclinical enabling studies and associated tasks leading to the filing

Preclinical models support animal models and animal replacement technologies development and refinement as well as testing services, ranging from screening and proof-of-concept to GLP efficacy studies.

This Gene Set Enrichment-type test designed for analysis of microarray and RNASeq data is designed to provide a faster, more accurate, and easier to understand test for gene expression studies. QuSAGE extends previous methods with a complete probability density function (PDF).